ArticleDiabetes, obesity & metabolism2026
Higher Serum Testosterone Protects Against the Development of Type 2 Diabetes in Middle-Aged but Not Older Men.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Higher Serum Testosterone Protects Against the Development of Type 2 Diabetes in Middle-Aged but Not Older Men.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLow serum testosterone concentration has been reported to be causally linked to the risk of Type 2 diabetes (T2D). The benefit of T2D protection has been demonstrated to continue up to serum testosterone concentrations of 461 ng/dL (16 nmol/L). It is unclear if there is an upper threshold for this effect of testosterone nor whether this causal process is moderated by age, waist circumference (WC) or baseline glycaemia (A1c).
aimTo examine the effect of WC, age and baseline glycaemia on the relationship between testosterone and incident T2D risk.
methodsMen without T2D, cancer or testosterone treatment and with baseline and 5-year follow-up assessments in the Men Androgen Inflammation Lifestyle and Environment Study cohort were included. The association between baseline testosterone and 5-year incident T2D was assessed using confounder-adjusted logistic regressions, with and without restricted cubic splines and pairwise interactions with age, WC and baseline A1c. Primary analyses were in the complete case set, with multiple imputation being performed as a sensitivity analysis.
resultsThe analysis included 1299 men with 109 cases of 5-year incident T2D (8.4%). An independent inverse relationship between serum testosterone concentration and 5-year incident T2D was observed (OR = 0.92, 95% CI = [0.87, 0.97], p = 0.001). There were no detectable interactions between testosterone and either WC (p = 0.93) or baseline A1c (p = 0.38). There was, however, evidence for a strong interaction between testosterone and age (p = 0.003), with low testosterone being associated with elevated T2D risk only in younger men.
conclusionsThese data suggest that higher concentrations of serum testosterone are protective against incident T2D in younger but not older men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.